Gilead Sciences, Inc.
GILD
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $183.9B
$148.51
▲ +0.28%
P/E
-55.62
Mkt Cap
$183.9B
52-Wk Range
$108.46–$157.29
52-Week Range
$108.46 - $157.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Extensive portfolio of FDA-approved blockbuster drugs with strong market positions
- Established global distribution network and manufacturing capabilities
- Strategic partnerships with leading biotech and pharmaceutical companies
- Significant R&D pipeline and expertise in virology and immunotherapy
- Strong cash flows enabling continued investment in innovation
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expansion of HIV treatment market with next-generation antiretroviral therapies
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Strong
+10.8% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Solid
2.17% yield
Smart-money signal
Who's buying GILD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 3, 2026
Reported EPS of -$6.75 vs -$7.25 consensus (+6.9% surprise). Revenue of $7.8B vs $7.4B expected (+5.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.9%
Revenue trend · last 8Q
—
+6%
-0%
+2%
+3%
+5%
+4%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$7.5B
$7.6B
$6.7B
$7.1B
$7.8B
$7.9B
$7.0B
$7.8B
Margins · last 8Q
Gross
-69.7%
Operating
-133.2%
Profit
-25.9%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Aug 5, 2026
vs Industry
How GILD stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related